Abstract 215P
Background
mnccRCC had a poor response to VEGF-targeted tyrosine kinase inhibitors (TKIs) and the first-line therapy was still limited. Our real-world study aimed to evaluate the effectiveness of tislelizumab-axitinib combination therapy versus TKI monotherapy as the first-line regimen in patients (pts) with mnccRCC.
Methods
Pts with mnccRCC received first-line therapy were identified between Jul. 2019 and Dec. 2022 in Sun Yat-sen University Cancer Center. Pts received first-line TKI monotherapy (TKI group, mainly sunitinib) or tislelizumab plus axitinib therapy (T+A group). Baseline characteristics, objective response rate (ORR), progression-free survival (PFS), PFS2 (defined as time from initial treatment to progression after first subsequent therapy or any-cause death.) and overall survival (OS) were retrospectively collected. The differences on effectiveness between the two groups were compared.
Results
Totally 39 pts were included, with a median age of 46 (17-72) years. 77.1% had an IMDC intermediate/poor-risk disease. 53.8% had papillary RCC, 19.5% had Mit family translocation RCC, 12.1% had chromophobe RCC and others had unclassified RCC. The median follow-up was 23.7 (18.5-29.0) months. The T+A group (n=20) had a significantly longer PFS compared with the TKI group(n=19) (median PFS (95% CI): 11.0 (8.1-14.0) vs 4.6 (3.0-6.2) months, P<0.001). Similarly, ORR was remarkably improved in the T+A group (40.0% vs 10.5%, P=0.006). The PFS2 did not come to the significant difference between the T+A group and TKI group (median PFS2 (95% CI): 18.6 (NR-NR) vs 12.0 (7.9-16.2) months, P=0.646). Median OS was not reached for T+A group and TKI group (median OS (95% CI): NR vs 39.6 (NR-NR) months, P= 0.176).
Conclusions
Tislelizumab plus axitinib could be an effective first-line regimen option for mnccRCC pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract